* allergy to hcq. * pregnancy or breastfeeding. * known history of retinal disease not related to macular degeneration, or preexisting eye retinopathy. * having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia. * having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. * having dermatitis, psoriasis, or porphyria. * history of lung disease or pneumonia not related to covid-19. * taking cyp450 enzyme-inducing medications within 4 weeks of the start of taking hcq (ex: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine. * currently taking qt-prolonging medications, which may include antiarrhythmics, quinolones, macrolides, select antipsychotics and antidepressants. * team members planning to have major abdominal, thoracic, spine or cns surgery during the protocol period

* allergy to hcq. * pregnancy or breastfeeding. * known history of retinal disease not related to macular degeneration, or preexisting eye retinopathy. * having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia. * having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. * having dermatitis, psoriasis, or porphyria. * history of lung disease or pneumonia not related to covid-19. * taking cyp450 enzyme-inducing medications within 4 weeks of the start of taking hcq (ex: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine. * currently taking qt-prolonging medications, which may include antiarrhythmics, quinolones, macrolides, select antipsychotics and antidepressants. * team members planning to have major abdominal, thoracic, spine or cns surgery during the protocol period

- allergy to hcq. - pregnancy or breastfeeding. - known history of retinal disease not related to macular degeneration, or preexisting eye retinopathy. - having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia. - having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. - having dermatitis, psoriasis, or porphyria. - history of lung disease or pneumonia not related to covid-19. - taking cyp450 enzyme-inducing medications within 4 weeks of the start of taking hcq (ex: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine. - currently taking qt-prolonging medications, which may include antiarrhythmics, quinolones, macrolides, select antipsychotics and antidepressants. - team members planning to have major abdominal, thoracic, spine or cns surgery during the protocol period

- allergy to hcq. - pregnancy or breastfeeding. - known history of retinal disease not related to macular degeneration, or preexisting eye retinopathy. - having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia. - having a prior history of glucose-6-phosphate dehydrogenase (g-6-pd) deficiency. - having dermatitis, psoriasis, or porphyria. - history of lung disease or pneumonia not related to covid-19. - taking cyp450 enzyme-inducing medications within 4 weeks of the start of taking hcq (ex: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine. - currently taking qt-prolonging medications, which may include antiarrhythmics, quinolones, macrolides, select antipsychotics and antidepressants. - team members planning to have major abdominal, thoracic, spine or cns surgery during the protocol period